Stock Taper 
CNSY
$3.07
▲ UP 2.33% (0.07)
KEY STATISTICS
Market Cap$21.13 M
52w High$23.50
52w Low$2.90
Dividend Yield—
Frequency—
P/E-0.43
Volume106.24K
Shares Out.6.88M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Marc H. Hedrick
ABOUT
SECTOR
Healthcare
WENT PUBLIC
August 3, 2026
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
28
UPCOMING EARNINGS
DateOct 29, 2026
DayThursday
Rev. Est.$1.42M
OCT
29
THU
PRICE
$3.07 ▲ UP 2.33% (+$0.07)About Cerenome, Inc.
http://www.plustherapeutics.com ↗Plus Therapeutics, Inc., a Houston-based clinical-stage pharma company founded in 1996, develops chemotherapeutics and radiotherapeutics like Rhenium NanoLiposome and DocePLUS for rare cancers with unmet medical needs.
INDUSTRY
Medical - Pharmaceuticals
A PRODUCT CERENOME, INC. IS KNOWN FOR
CNSide® Diagnostic
CNSide® is a reimbursed diagnostic platform that analyzes cerebrospinal fluid to detect and characterize CNS cancer cells, aiding diagnosis, monitoring, and treatment guidance within Cerenome's CNS oncology approach.
ETFS HOLDING THIS STOCK
ETFS HOLDING
11
LISTED HERE
1
RANKED BY POSITION SIZE
RATINGS SNAPSHOT
Overall rating: C
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
